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Abstract
Introduction Currently, osteoporosis research is rarely
undertaken in males but an increase in male life expectancy
in the company of hypogonadism suggests the necessity for
potential therapeutic options.
Materials and methods  In this study, the changes in bone
structure under standardized testosterone- (T), raloxifene-
(R) and estrogen (E)-supplemented diets were analyzed in
osteoporotic castrated male rats.
Results  Unexpected biomechanical results could be only
explained by the histomorphometry, but not by BMD mea-
surements obtained from the qCT. All tested substances
showed a signiWcant improvement in the trabecular net-
work (trabecular bone area for C: 2.55 mm2, T: 4.25 mm2,
R: 4.22 mm2 and E: 4.28 mm2), and suggests that the bone
structure was preserved. For the metaphyseal cortical bone,
a signiWcant loss was detected in T (CBP: 18.7%) compared
to R (CBP: 30.0%), E (CBP: 26.8%) and even to the osteo-
porotic control (CBP: 28.6%). This explains the observed
early mechanical Wnal failure after T supplementation.
However, due to the preserved trabecular bone in T, the
occurrence of the Wrst microfractures (yL: 49 § 21.4 N)
was signiWcantly later than in the osteoporotic control (yL:
39.5 § 15.5 N). Raloxifene performed well in hindering the
bone loss associated with osteoporosis. However, its eVect
(yL: 83.3 § 16.5 N) did not approach the protective eVect
of E (yL: 99.2 § 21.1 N).
Conclusion Testosterone only preserved the deterioration
of the trabecular bone but not of the cortical bone. Raloxif-
ene prevented the bone loss associated with osteoporosis at
all bony structures. This eVect did not approach the protec-
tive eVect of estrogen on trabecular bone, but it is more
suitable for male individuals because it has no feminizing
eVects on the subject.
Keywords Osteoporosis · Testosterone · Raloxifene · 
Fracture risk · Hypogonadism · Bone
Introduction
Osteoporosis has become a pertinent topic in public health
today, primarily due to the ever increasing elderly popula-
tion. Many of the current therapies target postmenopausal
osteoporosis [1, 2], where estrogens have been shown to
have potent anti-osteoporotic properties. However, an
increase in life expectancy in males also suggests the neces-
sity to develop potential alternative therapies since estro-
gens cannot be used in males because of their feminizing
side eVects. Osteoporosis research is rarely undertaken in
males and there are few therapeutic options. Testosterone
(T) is an essential hormone for maintenance of bone mass
and androgens have anti-osteoporotic properties [3,  4].
However, the clinical signiWcance of testosterone substitu-
tion in osteoporotic men with hypogonadism is still unde-
Wned. It is believed that estrogens mediate the primary
bone-sparing eVects of androgens only after aromatization [5].
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Aromatase gene expression and activity has been
demonstrated in bones of male humans and rodents [6–8]
Aromatase knock-out mice, as well as estrogen receptor 
knock-out mice develop osteoporosis [7, 8]. Additionally,
osteoblasts and osteoclasts were equally active in both con-
trol and testosterone-treated groups, while a reduction in
their activities was associated with estrogen- and raloxif-
ene-supplemented diets [6].
In males, osteoporosis occurs primarily due to slowly
deteriorating testicular testosterone production. Therefore,
T supplementation presents itself as an alternative treat-
ment that was tested in the present study. In recent years,
the discovery of selective estrogen receptor modulators
(SERMs) has led to the availability of substances, which do
not aVect the mammary glands and gonads, but exert estro-
genic, positive eVects in bone. One such substance is
raloxifene (R), which proved to have potent anti-osteopo-
rotic eVects in postmenopausal women [9, 10]. R appears to
have no feminizing eVect or negative eVects on male
gonads [11]. Therefore, R was also tested in this study.
The castrated rat is an established model of osteoporosis
[12, 13] and these animals develop substantial osteoporosis
with the highest degree occurring in the metaphyseal tibia
[14]; after 3 months, bone mass will decrease to about 35%
in male animals [14, 15]. Consequently, bone density mea-
surements are performed at the femoral neck for humans
and in the proximal tibia for rats. The qCT is an established
method used to quantify the eVect of anti-osteoporotic
agents in vivo [2, 16, 17]. Post-mortem microradiographs
from undecalciWed histological sections provide higher
local resolution. Information about the trabeculae (i.e.,
number, length, width, localization etc.), and changes in
cortical bone can also be obtained in detail.
Materials and methods
Animals and chemicals
The study protocol was approved by the regional govern-
ment and conformed to German animal protection laws
(permission Az: 509.42502/01-02.98 District Government
of Braunschweig).
Forty-four 3-month-old male Sprague-Dawley rats
(Winkelmann, Borken, Germany) weighing 220–260 g
were orchidectomized under Rompun/Ketanest anesthesia
(3.5 V/V, 1 ml/kg BW). After the operating procedure,
animals were divided into four groups: Group I received
phytoestrogen-free pelleted food (where protein supple-
mentation was substituted with potato proteins); Group II
received phytoestrogen-free food supplemented with T (in
the form of testosterone propionate) with the average intake
of 50 mg T/day; Group III received phytoestrogen-free
food supplemented with R where the average intake was
3.35 mg R/day; Group IV received phytoestrogen-free food
supplemented with E (in the form of estradiol benzoate),
where the average food and E intake per animal per day
was 20 g and 0.5 mg, respectively.
Drugs were used in established concentrations [2, 6, 17–
19]. Animals were fed with these speciWc diets for
12 weeks, after which time they were sacriWced under anes-
thesia. Both tibiae were prepared as follows: skin, muscles
and tendons were removed and the Wbula was separated at
the synostosis. Tibiae were immediately stored at ¡80°C
prior to histological embedding. The metaphysis of the left
tibia was used for immunohistochemical investigations as
previously described [6, 16].
Serum analyses
Collected blood samples were allowed to clot and then cen-
trifuged at 3,000 g, 10 min. Serum concentrations of T and
estradiol-17 were quantiWed using Euless (Roche, Mann-
heim, Germany) and DSL (Webster, TX, USA) commercial
immunoassays, respectively. To avoid the diVerence in T
and estradiol level, all blood samples are taken at a certain
time in the mornings.
BMD measurement
Twelve weeks after orchidectomy or on supplemented diets
with T, R and E, total BMD, total bone area (TBA), trabec-
ular density and trabecular area of the proximal tibial
metaphysis were recorded by qCT (STRATEC XCT 4.50,
Stratec Inc., Pforzheim, Germany) in anesthetized animals.
The scanner was positioned in the proximal plane of the left
tibial metaphysis and a coronal computed radiograph
(Scout view) in the distal direction was carried out. Image
acquisition, processing and calculation were performed
using the software package (XCT 5.40, STRATEC Inc.
Pforzheim, Germany). Trabecular values were calculated
by acquiring data within the default threshold of 280–
710 mg/cm3. Cortical area and cortical density were calcu-
lated from a slice sampled 15 mm distal to the growth plate.
A density above 710 mg/mm3 was regarded to be cortical
bone.
Biomechanical testing
A ZWICK-testing machine type 145660Z020/TND
(Zwick/Roell, Ulm, Germany) with a measuring range from
2 to 200 N at a relative accuracy of 0.2% at 0.4%FN and a
newly developed device as previously described [18] were
used for mechanical testing of the metaphyseal tibia.
Strength admission was recorded using “testXpert” soft-
ware. The speed of the feed motion was 50 mm/s and theWorld J Urol (2009) 27:547–555 549
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automatic switch oV-pressure was set at 300 N. The left
tibiae were thawed and continuously moistened with iso-
tonic saline solution during the test. The procedure was per-
formed blindly with regard to the test groups.
Preparation for microscopy and microradiography
After biomechanical testing, complete tibiae were defatted
in an alcohol series, stained with basic fuchsine (Chroma-
Gesellschaft, Koengen, Germany) and embedded in methyl
methacrylate. After polymerization, 100 m (§ 10) thick
sections were cut parallel to the surface of the knee joint
using a speciWcally designed diamond-coated saw (Leica
SP 1600 saw microtome, Bensheim, Germany) with a blade
thickness of 300 m. The level of the sections was calcu-
lated in order to obtain one speciWc section corresponding
to 2 mm distal to the growth plate. Therefore, this section
corresponds to the qCT slice, as described above. Micro-
radiographies were performed on KODAK Professional
Industrex SR45 Wlm (100 NIF) on a Faxitron X-Ray Sys-
tem (Hewlett-Packard, San Diego, CA, USA) as previously
described. The bone sections were exposed for 6 min at
40 kV and the resolution of the images was approximately
0.5 m. The Wlm was analyzed qualitatively and quantita-
tively under the microscope.
Qualitative and quantitative bone morphometry
Quantitative analysis of bone tissue was digitally deter-
mined in the microradiographs using the Quantimet system
(Leica DM-RXE and Leica QWIN, Bensheim, Germany)
after digital imaging with the Leica DC200 camera. The
following data were evaluated: TBA, trabecular bone area
(Tb.Ar.), percentage of trabecular bone (Tb.P.), trabecular
length (Tb.Ln.), number of trabecular nodes (N.Nd.), corti-
cal bone area (Cb.Ar.), percentage of cortical bone, cortical
width lateral (Ct.Wi.l.), cortical width medial (Ct.Wi.m.)
and the ratio of cancellous bone area and Tb.Ar. The last
value represents the trabecular density. Finally, fracture
lines from the previously performed biomechanical testing
[18] were analyzed qualitatively.
Statistics
For statistical analyses, the mean values and standard devi-
ations for each parameter were calculated. The diVerences
between the four tested substances were assessed using
ANOVA followed by the Tukey–Kramer post hoc test. For
determining the correlation between the microradiographic
and biomechanical data, Pearson’s correlation coeYcient
(r) was calculated. This value can range from ¡1.0 to 1.0
(where ¡1.0 = perfect negative correlation, 0.0 = no corre-
lation and 1.0 = perfect positive correlation).
Results
Serum analyses
The mean serum concentration of testosterone in the T-
treated animals was 4.2 § 0.8 ng/ml and in the estradiol-
17-treated animals, the mean E level was 51.6 § 4.6 pg/ml.
Both hormone levels fall within the normal circadian physi-
ological range of male and female rats; hence these animals
can be referred as normal (positive) controls. There is cur-
rently no established method to determine the serum levels
of raloxifene.
Body weight
At the time of castration, the average body weight for
control animals was 242.8 § 7.0 g and for the T-, R- and
E-treated groups, 259.3 § 45.2, 280.3 § 26.1 and 245.2 §
13.3 g, respectively. The average body weight of R-treated
rats was signiWcantly higher than for control and E-treated
animals. Three months after castration, diverse increases in
weight were observed amongst the animal groups, the
control and T-treated animals weighed 392.8 § 19.7 g
(+38.2%) and 393.4 § 23.4 g (+34.1%), respectively, whereas
treatments with R and E were associated with a signiW-
cantly lower animal body weights of 319.3 § 22.0 g
(+12.2%) and 270.1 § 18.9 g (+9.3%), respectively. For E
this is a well-known eVect [20, 21].
BMD and bone areas (qCT)
Total BMD and bone area, as well as trabecular and cortical
areas and densities at the metaphyseal tibia were obtained
3 months after castration and onset of T-, R- or E-supple-
mented diets. With T supplementation, only the value
“trabecular density” (178.4 § 34.61 mg/cm3) showed sig-
niWcant preservation compared with the osteoporotic
control group (135.8 § 13.24 mg/cm3) (Fig. 1d). Regarding
R- and E-treated bone, a signiWcant enhancement in
both total BMD (R: 788.3 § 97.24 mg/cm3, E: 765.9 §
108.6 mg/cm3) and trabecular density (R: 186.4 §
51.42 mg/cm3, E: 175.9 § 38.54 mg/cm3) was observed
compared to the osteoporotic C (tBMD: 701.1 § 129.5
mg/cm3). Interestingly, the trabecular areas for the R
(4.12 § 1.73 mm2) and E groups (4.19 § 1.84 mm2) were
signiWcantly lower than in the control (5.74 § 2.51 mm2)
and in the T group (5.70 § 2.50 mm2). For E this is
explainable by the signiWcantly lower TBA (E: 11.99 §
3.12 mm2, C: 14.34 § 3.80 mm2; T: 14.16 § 4.27 mm2,
R: 14.41 § 6.86 mm2). The values “cortical density”
(C: 1,208 § 64.58 mg/cm3, T: 1,195 § 65.71 mg/cm3,
R: 1,237 § 98.59 mg/cm3, E: 1,243 § 53.29 mg/cm3,) and
“cortical area” (C: 6.44 § 0.79 mm2, T: 6.25 § 0.66 mm2,550 World J Urol (2009) 27:547–555
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R: 6.97 § 2.29 mm2, E: 5.69 § 0.69 mm2) measured in
the qCT were very similar between all animal groups
(Fig. 2b).
Biomechanical testing
On the basis of established strength graphs, the maximum
force (Fmax) and yield load (yL) were calculated. The aver-
age yield load amounted to 39.5 § 15.5 N for the osteopo-
rotic C group, 49 § 21.4 N for T-treated, 83.3 § 16.5 N for
R-treated and 99.2 § 21.1 N for E-treated animals, respec-
tively. All diVerences between the test groups regarding the
yL were signiWcant (Fig. 3a). The average Fmax amounted
to 76.7 § 12.5 N for the C and 74.8 § 15.7 N for the T
group. They were signiWcantly lower than in the R (111.0 §
10.9 N) and the E groups (114.3 § 17.4 N) (Fig. 3b).
Microradiography and morphometry
A signiWcant improvement in all trabecular values Tb.Ar.,
Tb.P. and N.Nd. were clearly visible (Fig. 4) and could be
detected for all tested substances compared to those values
for the osteoporotic control (Table 1; Fig. 1a–c). E versus R
showed only minor diVerences, whereas E preserved the
trabecular bone slightly more (more Tb.P., more N.Nd. and
therefore shorter Tb.Ln.). It should be noted that all cortical
values (Cb.Ar., Cb.P., Ct.Wi.l. and Ct.Wi.m.) after T sup-
plementation were signiWcantly lower than the R, E and
even than the control group (Table 1; Fig. 2a). Under E and
R supplementation, the Cb.Ar.s were also signiWcantly
lower than in control animals, but with regard to the TBAs,
only the Cb.P. of the T group showed a signiWcantly lower
value (Table 1). Corresponding with these results, the
Fig. 1 Analysis of the trabecular structure of the metaphyseal tibia in
male rats in the microradiography. a Trabecular bone area (mm2),
b absolute number of nodes (No) and c trabecular bone area density
(%). Comparison to d trabecular density (mg/cm3) measured by the
qCT. Values are expressed as the mean § SD (*P < 0.01 vs. control,
#P < 0.01 vs. E, + P <0 . 0 1  v s .  R )
Fig. 2 Analysis of the cortical structure of the tibia in male rats. a
Microradiographic evaluation of the metaphyseal cortical bone area
(mm2), and b diaphyseal cortical density (mg/cm3) determined by the
qCT. Values are expressed as the mean § SD (*P < 0.01 vs. control,
+ P < 0.01 vs. R)World J Urol (2009) 27:547–555 551
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cortical width (Ct.Wi.l., Ct.Wi.m.) was signiWcantly
smaller in the E- and T group compared to the C group. For
R, the cortical widths were higher than in C; the consider-
ation of the Cb.P. values of R argues that there is a homoge-
neous distribution of the cortical bone.
Pearson correlation test
Table 2 shows the correlation between the microradiographic
and biomechanical data of the animal experiments. A signiW-
cant negative correlation was found between Fmax, the yield
load and the TBA, respectively. Fmax also correlated in a sig-
niWcant but positive manner with the cortical width, density
of the trabecular bone and trabecular length. The yield load
correlated signiWcantly with nearly all trabecular values. In
summary, elasticity and the avoidance of microfracturing,
depend on the trabecular network, whereas the occurrence of
a visible fracture depends on the combination of all bone
parameters (TBA, cortical and trabecular bone).
Analysis of the post-mortem fracture lines
Examination of the microradiographs allowed the diVer-
ences in the fracture lines from the biomechanical testing to
be determined in all groups. In an example picture from an
osteoporotic control (Fig. 4a, e), the main fracture line is
clearly visible. In this group fracture lines failed in a burst-
like fashion with no regard for the bone architecture and
matrix. In contrast, in the E-supplemented group, the main
fracture line spread with many comminutions of various
lengths (Fig. 4d, h) and the force appeared to propagate
directly through those bone structures with least resistance
(i.e., the fracture “cuts” through the thinnest trabecular
junctions). In the R group (Fig. 4c, g), this phenomenon
was less developed compared to the E group, although
more visible. After T supplementation, less comminution
were found, although the trabecular network was nearly as
dense as those present in R- and E-treated bones
(Fig. 4b, f). However, the administered force aVected the
trabecular structures more than in the other groups because
of the weaker cortical bone.
Discussion
Management of hypogonadism and its related morbidities
in male is still a dilemma in medicine. Hypogonadism has
been accepted as a signiWcant risk factor for the develop-
ment of male osteoporosis. However, studies regarding
therapy of osteoporosis in males are rare in comparison to
those of postmenopausal females. The orchidectomized rat
is currently an accepted animal model of male hypogonad-
ism and osteoporosis [22, 23].
Tested substances
The eVects of testosterone may be mediated directly by the
androgen receptor or indirectly, via aromatization into
estrogens and subsequent stimulation of estrogen receptors
(ER- and ER-) [24, 25]. It preserved the trabecular struc-
ture (Tr.Ar., N.Nd.) signiWcantly compared to the osteopo-
rotic control. The protective eVect was nearly as good as for
estrogen and raloxifene (Fig. 1a, b). The investigation of
the metaphyseal cortical bone in the microradiography
showed interesting results regarding testosterone. In con-
trast to results described by other authors [23–25], a signiW-
cant deterioration in cortical bone was found after T
supplementation. Cortical bone was more reduced than in
the R- and E-treated groups, even more than in the osteopo-
rotic control. The reason for this lack of conformity may be
that metaphyseal (tibial) bone was investigated instead of
diaphyseal bone, as was investigated in these other previous
studies. A possible explanation for this phenomenon may
be that the cortical bone has less androgen and/or estrogen
receptors, but that has not been proved yet.
The structural changes after testosterone-supplementa-
tion could explain the comparatively poor results in the
Fig. 3 Results of the biomechanical testing of the metaphyseal tibia in
male rats. a Plastic deformation determined by the yield load (N) and
b Wnal failure determined by Fmax (N). Values are expressed as the
mean § SD (*P < 0.01 vs. control, #P < 0.01 vs. E, + P <0 . 0 1  v s .  R )552 World J Urol (2009) 27:547–555
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biomechanical tests (Fig. 3). The reduced cortical bone
failed early and led to a low Fmax. However, the dense tra-
becular structure (Tr.Ar., N.Nd.) did protect the bone since
it had high elasticity. Therefore, the yL is signiWcantly
higher than in the osteoporotic C. Microfracturing, which is
the basis of the osteoporotic fracture, occurred later in T
than in C. These data suggest that if T is to be used in treat-
ment of osteoporosis, it needs to be supplemented by
another bone-sparing substance, i.e., bisphosphonates as an
osteoclast inhibitor.
Estrogen plays a key role in male skeletal growth
[26, 27]. In this study preserved the trabecular bone more
than T and R. It is well-acknowledged that estrogen appli-
cation in rats’ results in smaller animals with a lower body
weight [27]. Therefore, the signiWcantly smaller TBA must
be taken into consideration; the number of nodes and
Fig. 4 Microradiographic 
sections of the metaphyseal tibia 
made 2 mm distal to the growth 
plate of the tibia from an a 
osteoporotic control animal 
(ORX), b testosterone (T)-, 
c raloxifene (R)- and d estradiol 
(E)-treated rat, viewed under 
30-fold (a–d) and 60-fold (e–h) 
magniWcation. Bursting of the 
osteoporotic bone with 
additional rupture of the lateral 
and medial cortical bone (a, e), 
winding fracture lines with a 
various number of 
comminutions in the treatment 
groups. Decreasing destruction 
of the bone from f the T- to g the 
R- up to h the E groupWorld J Urol (2009) 27:547–555 553
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relation of trabecular volume to tissue volume to cancellous
volume were remarkably high. However, supplementation
of E does not seem to improve the cortical bone in compar-
ison to C. When considering biomechanical features, this
had no negative eVect since the comparable thin cortical
bones seemed to have good elasticity and resistance to
forces. The measured yL for E was the highest and signiW-
cantly better than for C, T and R. Plastic deformation and
microfracturing occurred very late. In terms of Fmax, the
bone quality was signiWcantly better than in C and T; only
R showed equal results to E. E protected the physiological
bony structure with a deWned mixture of elastic and calci-
Wed tissues.
The SERM raloxifene that had been proved to prevent
postmenopausal osteoporosis [9, 10] was also investigated.
It did not bind to androgen receptors, had no eVects on male
reproduction (sperm production/quality, testicular weight
and histopathology) [11] and had positive eVects on the
serum cholesterol [11] and the elasticity of vessels [21].
Therefore, it may also be a good option in the treatment of
osteoporosis in males. In osteoporotic rats, it mimicked
most preserving eVects of E, but did not yet reach the levels
that E did in all parameters. Supplementation of R pre-
served the structure of the osteoporotic bones signiWcantly.
This was true for the metaphyseal cortical bone as well as
the trabecular bone. In comparison to E, R preserved corti-
cal bone more, but the trabecular bone was preserved less
well than E. Overall, the bone volume (per tissue volume)
was highest in R. That supports the well-acknowledged fact
that the structure of bone is more important than the bone
mass regarding the question of capacitance. The Wnal
failure (Fmax) for R was equal to E. But the yield load,
which is more interesting in osteoporosis, was signiWcantly
lower than in E. Fatigue fractures in osteoporosis as the
result of the sum of microfractures would occur signiW-
cantly earlier. Regarding the prophylaxis of osteoporosis E
outperforms R.
Morphological methods
The morphological analysis with the qCT and microradiog-
raphy showed that the tested substances T, R and E
improved the trabecular structure. The qCT seemed to be
less qualiWed for analysis of the minor metaphyseal cortical
Table 1 Morphological analysis of the cortical and trabecular bone in the microradiographic sections 2 mm distally to the growth plate in the
metaphyseal tibia in male rats
a SigniWcant versus ORX control group
Osteoporotic control Testosterone Raloxifene Estrogen
Total bone area (mm2; mean) 23.66 § 2.26 24.67 § 3.11 23.37 § 3.39 20.99 § 2.54a
Trabecular bone area (mm2; mean) 2.553 § 0.90 4.253 § 1.18a 4.223 § 1.10a 4.276 § 0.99a
Percentage of trabecular bone (%; mean) 10.62 § 2.994 17.01 § 3.223a 17.95 § 3.371a 20.18 § 2.909a
Trabecular bone area/cancellous bone area ratio 
(Tb.Ar./Cn.Ar.) (mean)
7.40 § 3.01 4.87 § 0.68a 4.19 § 0.71a 3.70 § 0.53a
Trabecular length (m; mean) 102.7 § 7.28 99.45 § 5.11 108.2 § 9.74 103.2 § 5.88
Number of nodes (mean) 150.3 § 59.87 311.1 § 140.10a 306.1 § 129.40a 365.6 § 122.20a
Cortical bone area (mm2; mean) 6.701 § 0.62 4.443 § 1.61a 6.165 § 0.77a 5.575 § 0.64a
Percentage of cortical bone (%; mean) 28.59 § 3.98 18.68 § 8.41a 30.02 § 4.41 26.77 § 3.10
Cortical width lateral (m; mean) 457.7 § 48.29 388.0 § 48.29a 498.6 § 36.87a 396.2 § 23.74a
Cortical width medial (m; mean) 324.1 § 21.33 254.4 § 41.95a 349.0 § 42.60 273.8 § 34.68a
Table 2 Positive and negative 
correlations of the morphologi-
cal data of the microradiograph-
ies and biomechanical testing 
evaluated in the Pearson test
Fmax Yield load
Pearson rR 2 Pearson rR 2
Total bone area ¡0.4964* 0.2464* ¡0.2937* 0.0863*
Trabecular bone area 0.1665 0.0277 0.4030* 0.1624*
Tb.Ar./Cn.Ar. ratio 0.5531* 0.3060* 0.6186* 0.3826*
Number of nodes 0.1885 0.0355 0.4773* 0.2279*
Trabecular length 0.3212* 0.1032* 0.2001 0.0400
Cortical bone area ¡0.2800 0.0784 ¡0.2736 0.0749
Percentage of cortical bone 0.2656 0.0706 0.1429 0.0204
Average cortical width 0.3226* 0.1041* ¡0.0407 0.0016
Pearson r and R2, representing 
the percentage of correlating 
values
* P < 0.005554 World J Urol (2009) 27:547–555
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bone. Microradiography was able to illustrate the diVerent
inXuences of the tested substances more precisely.
In clinical practice, microscopic evaluation or non-inva-
sive biomechanical measurement of bone quality for diag-
nostics or therapy of osteoporosis is not possible. It is well-
known that the true individual risk of fracture cannot be
measured by BMD alone. However, there is yet to be an
alternative device for estimating individual bone quality in
vivo. Micro-CTs for clinical examinations of human bone
are rare worldwide. They provide more detailed, but also
indirect parameters to estimate fracture risk. In the future, it
may be helpful to also investigate the non-calciferous bone
matrix and its changes during developing osteoporosis
(e.g., by an exploratory excision) because of its important
inXuence on the elasticity and brittleness of bone.
Conclusion
Testosterone only improved the trabecular bone structure,
however due to the loss of cortical bone, fragility was
nearly the same as that for osteoporotic bone. R had a good
eVect and hindered the bone loss associated with osteoporo-
sis at trabecular structures. However, its eVect did not
approach the protective eVect of E on the incidence of
microfractures, which form the basis of osteoporotic frac-
tures. E inhibited growth and induced smaller tibiae in rat,
which was also advantageous. Nevertheless, Raloxifene
may be a potential male osteoporosis treatment, as estrogen
cannot be used in males because of its feminizing eVects.
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